MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why WVE Stock slipped -0.28% Today — RQD Quant Desk Flash
$3.63 -0.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.62
Wave Life Sciences Inc. (WVE) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $715.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.62 (-0.24%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WVE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY WVE SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (41% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 49.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.46-9.5% Next Q
24
Q2 (-2Q)Grade E$3.13+1.6% Next Q
27
Q3 (-1Q)Grade E$3.18+14.2% Next Q
29
CurrentGrade E$3.63-9.2% Hist 90D α
32
Trajectory: E (24) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a WVE Turnaround Squeeze
While WVE currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.07) and Max Pain ($3.81) forces dealer call-delta covering toward $22.82.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $WVE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WVE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why WVE Stock slipped -0.28% Today — RQD Quant Desk Flash
Wave Life Sciences Inc. (WVE) slipped -0.28% to $3.63, trading at 3% of its 52-week range ($3.04 – $21.73). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($3.04 – $21.73) with RSI-14 at 49.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.63 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live WVE Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WVE)
- ✓Walkthrough of WVE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
WVE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.58%▼ DESCENDING CHANNEL
2026-10-30O $3.62H $3.70L $3.43C $3.63VOL 3.33M
RES: $5.35SUP: $2.51SMA50: $4.07SMA200: $7.42
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
WVE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -60.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on WVE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for WVE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WVE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WVE)
Health Care Rank #887 of 1016
⚔️ GYRE vs WVE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (WVE vs. GYRE, APMD, SGMT, DSGN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Wave Life Sciences Inc. (WVE) ranks #887 by composite RQD confidence (32/100, grade E) and #397 by equity capitalization ($715.9M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. APMD currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with WVE at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| WVE
ACTIVE
Wave Life Sciences Inc. | E | 32/100 | — | — | -35.0% | -0.28% | $715.9M | Benchmark Subject |
| GYRE Gyre Therapeutics Inc. | D | 46/100 | 72.3x | 95.4% | 25.4% | -9.59% | $714.8M | /gyre-vs-wve → |
| APMD Apnimed Inc. | D | 47/100 | — | — | — | -9.45% | $721.9M | /apmd-vs-wve → |
| SGMT Sagimet Biosciences Inc. (Series A) | E | 34/100 | — | — | -35.0% | -2.89% | $735.7M | /sgmt-vs-wve → |
| DSGN Design Therapeutics Inc. | D | 45/100 | — | — | -32.1% | -0.18% | $692.2M | /dsgn-vs-wve → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001631574In its most recent audited fiscal period (FY2025, filed 2025-12-31), Wave Life Sciences Inc. (WVE) reported GAAP revenue of $42.7M (-60.5% vs. FY2024 revenue of $108.3M , and -62.3% cumulative change since FY2023) , GAAP net income of -$204.4M, operating cash flow of -$187.5M, and free cash flow of -$188.2M (-23.9% YoY). On the balance sheet, WVE closed FY2025 with $638.5M in total assets against $0 in total debt (Altman Z-Score: 0.85, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $42.7M | -$204.4M | -$187.5M | -$188.2M | $638.5M | — |
| FY2024 (FY) | 2024-12-31 | $108.3M | -$97.0M | -$151.0M | -$152.0M | $352.2M | — |
| FY2023 (FY) | 2023-12-31 | $113.3M | -$57.5M | -$19.4M | -$19.4M | — | — |
3. WVE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs WVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Wave Life Sciences Inc. (NASDAQ: WVE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.63 (-0.28% 1D, market cap $715.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, WVE ranks #887 in composite RQD confidence.
How does WVE compare to GYRE and APMD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WVE carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D grade (46/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M) and APMD (Apnimed Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $721.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for WVE?
Per WVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631574), Wave Life Sciences Inc. generated $42.7M in revenue (-60.5% YoY), -$204.4M in net income, and -$188.2M in free cash flow against $638.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is WVE trading relative to its 50-day, 200-day, and 52-week technical levels?
WVE last traded at $3.63 (-0.28% on volume of 3,593,679 shares), positioning the stock -10.81% below its 50-day simple moving average ($4.07) and -51.08% below its 200-day simple moving average ($7.42). Across its 52-week range of $3.04 to $21.73, WVE sits at the 3.2% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.18 to $4.08).
WVE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is WVE stock moving today?
Why WVE Stock slipped -0.28% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.